This document represents an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF) first published in 2012 and updated in 2015.1 This guideline aims to provide healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of primary myelofibrosis (PMF), as well as post-polycythaemia vera myelofibrosis (post-PV MF) and post-essential thrombocythaemia myelofibrosis (post-ET MF). A section on prefibrotic MF is also included. A separate BSH Guideline covers the management of MF and is published alongside this guideline.
Declaration of Interests
All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.